Wed, November 30, 2011
[ Wed, Nov 30th 2011 ] - Market Wire
Watson Launches Generic LIPITOR
Tue, November 29, 2011
Mon, November 28, 2011
Sun, November 27, 2011
Fri, November 25, 2011
Thu, November 24, 2011
Wed, November 23, 2011
[ Wed, Nov 23rd 2011 ] - Market Wire
00 a.m. EST
Tue, November 22, 2011
[ Tue, Nov 22nd 2011 ] - Market Wire
BD Board Increases Dividend
Mon, November 21, 2011
Sun, November 20, 2011
Fri, November 18, 2011
Thu, November 17, 2011
Wed, November 16, 2011

NuPathe to Present at the Piper Jaffray 23rd Annual Healthcare Conference


//health-fitness.news-articles.net/content/2011/ .. r-jaffray-23rd-annual-healthcare-conference.html
Published in Health and Fitness on Tuesday, November 22nd 2011 at 10:41 GMT by Market Wire   Print publication without navigation


November 22, 2011 13:30 ET

NuPathe to Present at the Piper Jaffray 23rd Annual Healthcare Conference

CONSHOHOCKEN, PA--(Marketwire - Nov 22, 2011) - NuPathe Inc. (NASDAQ: [ PATH ]), an emerging biopharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, today announced that [ Jane Hollingsworth ], chief executive officer, will present a company overview at the Piper Jaffray 23rd Annual Healthcare Conference on Wednesday, November 30, 2011, at 4:00 p.m. EST. The conference is being held at The New York Palace Hotel in New York, NY.

A live audio webcast of the presentation will be available via the "Investor Relations" page of the NuPathe website, [ www.nupathe.com ]. Please log on through NuPathe's website approximately 10 minutes prior to the scheduled start time. A replay of the webcast will also be archived on the Company's website for 90 days following the presentation.

About NuPathe
NuPathe Inc. ([ www.nupathe.com ]) is an emerging biopharmaceutical company focused on innovative neuroscience solutions for diseases of the central nervous system including neurological and psychiatric disorders. NuPathe's lead product candidate, [ NP101 ], is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine. In addition to NP101, NuPathe has two additional proprietary product candidates in preclinical development: [ NP201 ] for the continuous symptomatic treatment of Parkinson's disease, which the company plans to partner, and [ NP202 ] for the long-term treatment of schizophrenia and bipolar disorder.



Publication Contributing Sources